Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RefillHA Volume+ is a combination medical device consisting of cross-linked hyaluronic acid and lidocaine, developed by BioScience GmbH. It is specifically designed for facial soft tissue augmentation and the correction of deep wrinkles and folds, such as nasolabial folds. The product functions by providing mechanical volume to the skin's layers, where the hyaluronic acid component acts as a physical filler to smooth depressions and restore facial contours. The inclusion of lidocaine serves as a local anesthetic to minimize pain and discomfort during the injection process. RefillHA Volume+ is typically administered via subcutaneous or intradermal injection by trained healthcare professionals. Its safety and performance in routine clinical settings have been evaluated in post-market clinical studies, such as NCT07109635.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on RefillHA Volume+.